Table 3 Plasma ANGPTL3 and association with liver markers
Liver markers | Function and association with liver steatosis | Baseline | Weight loss period | ||
|---|---|---|---|---|---|
β (95%CI) | p | β (95%CI) | p | ||
ALT (RFU) | Aminotransferase. High levels in liver. Marker of hepatocellular damage (↑). | − 0.78 (− 2.88; 1.31) | 0.463 | 0.02 (− 0.02; 0.05) | 0.405 |
AST (RFU) | Aminotransferase. High levels in the liver, heart, and muscle (↑). | − 1.00 (− 3.04; 1.04) | 0.336 | − 0.05 (− 0.08; − 0.02) | 0.004 |
Adiponectin (RFU) | Induce hepatic fatty acid oxidation, inhibits fatty acid synthesis, and suppress TNF-α production in the liver (↓). | 1.51 (− 0.53; 3.56) | 0.150 | 0.04 (0.00; 0.08) | 0.030 |
Fetuin A (RFU) | Glycoprotein produced predominantly by the liver. Inhibitor of the insulin receptor tyrosine kinase (↑). | − 0.97 (− 3.01; 1.06) | 0.347 | − 0.01 (− 0.04; 0.02) | 0.551 |
Fetuin B (RFU) | Shares 22% sequence similarity with fetuin A. Linked to inflammation and insulin resistance (↑). | 0.43 (− 1.70; 2.56) | 0.692 | 0.03 (− 0.03; 0.08) | 0.347 |
CK-18 (RFU) | Activation of caspase 3 (apoptosis) results in cleavage of CK-18, the major intermediate filament in hepatocytes (↑). | 5.90 (3.82; 7.99) | 1.03 × 10 −7 | 0.21 (0.15; 0.26) | 1.47 × 10 −13 |